Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
|Articles|September 16, 2008
- July15 2003
- Volume 10
- Issue 13
Coast-to-Coast Crime
Advertisement
The FBI has release is annual Uniform Crime Report (www.fbi.gov). The annual report, which offers up statistics on many crimes in US cities, showed that the nation's crime index actually fell by 0.2% last year; violent crime fell by about 1.5%. With quality of life issues in mind, here are some 2002 crime numbers for 5 major cites across the country:
Articles in this issue
about 18 years ago
Less Time, More Workabout 18 years ago
One Hand Giving, Another Taking?about 18 years ago
RIP-Steven C. Campabout 18 years ago
Pay Yourself Firstabout 18 years ago
ADDING TO THE MIXabout 18 years ago
SPAMMER SLAMMEDabout 18 years ago
AUDITING THE WEALTHYabout 18 years ago
UNDER THE IRS GUNabout 18 years ago
MEDICARE RUNAROUNDabout 18 years ago
REFINANCING & TAXESAdvertisement
Related to this article
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.
Advertisement
Advertisement
Trending on HCPLive
1
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Tips on Optimizing HS Biologics, Combinations, and Surgery
4
Why "Normal" Ferritin Can Miss Iron Deficiency, With Jacquelyn Powers, MD, MS
5